These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29688429)

  • 21. Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.
    Starenki D; Hong SK; Wu PK; Park JI
    Cancer Biol Ther; 2017 Jul; 18(7):473-483. PubMed ID: 28475408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The curcumin analog EF24 targets NF-κB and miRNA-21, and has potent anticancer activity in vitro and in vivo.
    Yang CH; Yue J; Sims M; Pfeffer LM
    PLoS One; 2013; 8(8):e71130. PubMed ID: 23940701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Curcumin Analog EF24 is Highly Active Against Chemotherapy- Resistant Melanoma Cells.
    He Y; Li W; Zhang J; Yang Y; Qian Y; Zhou D
    Curr Cancer Drug Targets; 2021; 21(7):608-618. PubMed ID: 33655859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
    Zhang L; Scorsone K; Woodfield SE; Zage PE
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):977-87. PubMed ID: 26407819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Curcumin Analogues DMC and EF24 in Combination with the Cytokine TRAIL against Kidney Cancer.
    Ibáñez Gaspar V; McCaul J; Cassidy H; Slattery C; McMorrow T
    Molecules; 2021 Oct; 26(20):. PubMed ID: 34684883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
    Starenki D; Hong SK; Lloyd RV; Park JI
    Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EF24 inhibits tumor growth and metastasis via suppressing NF-kappaB dependent pathways in human cholangiocarcinoma.
    Yin DL; Liang YJ; Zheng TS; Song RP; Wang JB; Sun BS; Pan SH; Qu LD; Liu JR; Jiang HC; Liu LX
    Sci Rep; 2016 Aug; 6():32167. PubMed ID: 27571770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EF24 induces ROS-mediated apoptosis via targeting thioredoxin reductase 1 in gastric cancer cells.
    Zou P; Xia Y; Chen W; Chen X; Ying S; Feng Z; Chen T; Ye Q; Wang Z; Qiu C; Yang S; Liang G
    Oncotarget; 2016 Apr; 7(14):18050-64. PubMed ID: 26919110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
    Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
    J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cabozantinib: a review of its use in patients with medullary thyroid cancer.
    Hoy SM
    Drugs; 2014 Aug; 74(12):1435-44. PubMed ID: 25056653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
    Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
    J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
    Ruan M; Liu M; Dong Q; Chen L
    J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impressive Suppression of Colon Cancer Growth by Triple Combination SN38/EF24/Melatonin: "Oncogenic"
    Bakalova R; Zhelev Z; Shibata S; Nikolova B; Aoki I; Higashi T
    Anticancer Res; 2017 Oct; 37(10):5449-5458. PubMed ID: 28982855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity.
    Subramaniam D; May R; Sureban SM; Lee KB; George R; Kuppusamy P; Ramanujam RP; Hideg K; Dieckgraefe BK; Houchen CW; Anant S
    Cancer Res; 2008 Mar; 68(6):1962-9. PubMed ID: 18339878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma.
    Lin H; Jiang X; Zhu H; Jiang W; Dong X; Qiao H; Sun X; Jiang H
    Tumour Biol; 2016 Jan; 37(1):381-91. PubMed ID: 26219898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EF24 Suppresses Invasion and Migration of Hepatocellular Carcinoma Cells
    Zhao R; Tin L; Zhang Y; Wu Y; Jin Y; Jin X; Zhang F; Li X
    Biomed Res Int; 2016; 2016():8569684. PubMed ID: 27999817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EF24 induces ferroptosis in osteosarcoma cells through HMOX1.
    Lin H; Chen X; Zhang C; Yang T; Deng Z; Song Y; Huang L; Li F; Li Q; Lin S; Jin D
    Biomed Pharmacother; 2021 Apr; 136():111202. PubMed ID: 33453607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The curcumin analog EF24 is a novel senolytic agent.
    Li W; He Y; Zhang R; Zheng G; Zhou D
    Aging (Albany NY); 2019 Jan; 11(2):771-782. PubMed ID: 30694217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
    Sherman SI; Clary DO; Elisei R; Schlumberger MJ; Cohen EE; Schöffski P; Wirth LJ; Mangeshkar M; Aftab DT; Brose MS
    Cancer; 2016 Dec; 122(24):3856-3864. PubMed ID: 27525386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.